Dice CEO: Energy, T...
Health Care: Drugs
Elan Corp PLC (ELN: NYSE)
$13.39 -0.57 | -4.08%
06/01/12 - 04:03 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 271.70M | 422.50M | 836.50M | 375.30M |
| Receivables | 167.70M | 191.60M | 192.40M | 196.10M |
| Inventories | 23.80M | 39.00M | 53.50M | 29.80M |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 518.00M | 920.50M | 1.16B | 762.00M |
| Property, Plant & Equipment, Gross | 146.10M | 695.80M | 657.50M | 637.20M |
| Accumulated Depreciation & Depletion | 62.90M | 408.30M | 364.70M | 285.40M |
| Property, Plant & Equipment, Net | 83.20M | 287.50M | 292.80M | 351.80M |
| Intangibles | 102.50M | 376.50M | 159.70M | 285.90M |
| Other Non-Current Assets | 723.80M | 278.70M | 301.50M | 54.60M |
| Total Non-Current Assets | 1.24B | 1.10B | 1.19B | 1.11B |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 1.75B | 2.02B | 2.35B | 1.87B |
| Accounts Payable | 46.40M | 39.20M | 52.40M | 37.70M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 276.30M | 481.70M | 250.50M | 280.30M |
| Long Term Debt | 615.00M | 1.27B | 1.54B | 1.76B |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 60.70M | 71.10M | 61.00M | 54.50M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 675.70M | 1.34B | 1.60B | 1.82B |
| Total Liabilities | 952.00M | 1.82B | 1.85B | 2.10B |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 801.80M | 194.30M | 494.20M | -232.20M |
| Common Par | 36.20M | 35.90M | 35.80M | 27.60M |
| Additional Paid In Capital | 6.49B | 6.44B | 6.41B | 5.52B |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -5.68B | -6.24B | -5.92B | -5.74B |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -37.40M | -43.10M | -36.10M | -38.80M |
| Total Capitalization | 1.42B | 1.46B | 2.03B | 1.53B |
| Total Equity | 801.80M | 194.30M | 494.20M | -232.20M |
| Total Liabilities & Stock Equity | 1.75B | 2.02B | 2.35B | 1.87B |
| Total Common Shares Outstanding | 589.35M | 585.20M | 583.90M | 471.41M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 587.60M | 584.90M | 506.80M | 473.50M |
| Diluted Weighted Shares Outstanding | 593.50M | 584.90M | 506.80M | 473.50M |
| Number of Employees | 412 | 1219 | 1321 | 1687 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ELN
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- ProGeorge Soros
- UserGFNN Stockdiagnostics 13
- ContributorBreakout Stocks Of The Week...
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
- ProRobert Bruce
- ContributorTechnical Setups for the We...
- Contributor10 Health Care Stocks With ...
Latest ELN Headlines from TheStreet
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- A Health Care Fortnight for the Record Books 05.14.12 | 07:05 am
- On Nowruz, Reviewing Drug Stock Picks 03.26.12 | 07:03 am
- Elan's Alzheimer's-Fueled Run Means Investors Are Forgetting the Past 03.19.12 | 07:03 am
- The Case for Shorting Elan Into Upcoming Alzheimer's Trial Results 02.21.12 | 07:02 am
- Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data 01.17.12 | 09:01 am
- 7 Relative Strength Stocks for 2012 12.29.11 | 05:12 pm
- 7 Stocks Hitting New 52-Week Highs 12.21.11 | 01:12 pm
- Your Vote Counts: Who is the Worst Biotech CEO of 2011? 12.01.11 | 10:12 am
- Good Biotech Stocks for a Bear Market 08.09.11 | 08:08 am
Press Releases for ELN
- Elan To Present At Jefferies 2012 Global Healthcare Conference - Business Wire 05.28.12 | 08:05 am
- New Analysis Of Risk Stratification For TYSABRI® Published In New England Journal Of Medicine - Business Wire 05.17.12 | 03:05 pm
- Elan Reports First Quarter 2012 Financial Results - Business Wire 04.26.12 | 02:04 am
- Elan Announces Webcast Of First Quarter 2012 Financial Results - Business Wire 04.12.12 | 04:04 pm
- Elan Raises $381 Million In Sale Of 76% Of Alkermes Holding - Business Wire 03.13.12 | 12:03 pm
- Elan Chairman Provides Update On CEO Succession - Business Wire 03.01.12 | 02:03 am
- Elan Reports Fourth Quarter And Full-Year 2011 Financial Results - Business Wire 02.08.12 | 02:02 am
- Elan To Present At The Leerink Swann 2012 Global Healthcare Conference - Business Wire 02.01.12 | 04:02 pm
- ASCEND Study To Evaluate The Effectiveness Of TYSABRI® (natalizumab) As A Treatment For Secondary-Progressive Multiple Sclerosis - Business Wire 01.26.12 | 08:01 am
- FDA Updates TYSABRI® (natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor - Business Wire 01.20.12 | 04:01 pm
Partner Headlines for ELN
- Healthcare Biz Recap: Express Scripts New Driver, Elan Pops - Wall St. Cheat Sheet 05.27.12 | 12:05 pm
- Billionaire Soros' Q1 High Conviction Buys In 2 Growth Stocks, Other Buys And Sells - Seeking Alpha 05.18.12 | 08:05 pm
- Revenues Climb at Acorda - Analyst Blog - Zacks 05.04.12 | 06:05 pm
- Elan Misses 1Q EPS, Revenues Rise - Analyst Blog - Zacks 05.01.12 | 09:05 am
- Elan Sells 76% Stake in Alkermes - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- Tuesday's Bio Pharma Watch List - Seeking Alpha 02.28.12 | 08:02 am
- Zacks Sell List Highlights: Expedia, NII Holdings, Elan and Gentex - Press Releases - Zacks 02.17.12 | 09:02 am
- NII HLDGS-CL B (NIHD) - Profit Tracks - Zacks 02.17.12 | 01:02 am
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company - Press Releases - Zacks 02.06.12 | 09:02 am
- The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases - Zacks 02.01.12 | 09:02 am
